The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis

HIGHLIGHTS

• who: Kristel S. Knudsen from the Participants were recruited from our outpatient clinic at the Department of Thoracic Medicine, Haukeland University Hospital, Norway, participating in The Microbiome in Interstitial Lung Disease study (MicroILD) [16] and The Bergen Chronic Obstructive Pulmonary Disease Microbiome study (MicroCOPD) [17]All study participants were examined in one center with consistent methodology by the same investigators. The MicroILD study included , patients in, of which , previously diagnosed with sarcoidosis. The sarcoidosis patients were in stable condition (, patients received a maximum , mg/day of prednisolone) and no participants received antibiotics , days before bronchoscopy. The MicroCOPD . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.